MicroRNA‐7 negatively regulates Toll‐like receptor 4 signaling pathway through FAM177A

Toll‐like receptor (TLR) 4 signalling is critical for innate immunoinflammatory response and widely triggers the development of various types of clinical diseases. MicroRNA‐7 (miR‐7) is well documented to play an important regulatory role in various biological events. However, the exact role of miR‐7 in TLR4 signalling pathway remains to be fully elucidated. In the present study, we found that miR‐7 expression in TLR4 signalling‐activated bone marrow‐derived macrophages (BMDMs) stimulated by LPS was dramatically increased. Importantly, miR‐7 deficiency significantly enhanced the production of related inflammatory cytokines including IL‐1β, IL‐6 and IL‐12, as well as TNF‐α, on LPS‐activated BMDMs, accompanied by elevated transduction of TLR4 signalling including Myd88‐dependent and Myd88‐independent pathways, whereas miR‐7 overexpression significantly decreased the transduction of TLR4 signalling and the production of related inflammatory cytokines. Mechanistically, we identified family with sequence similarity 177, member A (FAM177A) as a novel target molecule of miR‐7. Furthermore, down‐regulation of FAM177A using RNAi could impair the transduction of TLR4 signalling. Finally, down‐regulation of FAM177A also reversed the effect of miR‐7 deficiency on TLR4 signalling transduction and production of related inflammatory cytokines on BMDMs. Therefore, we provide the new evidence that miR‐7 acts as a novel negative fine‐tuner in regulating TLR4 signalling pathways by targeting FAM177A, which might throw light on the basal understanding on the regulatory mechanism of TLR4 signalling and benefit the development of therapeutic strategies against related clinical diseases.     

Reciprocal expression of IL‐25 and IL‐17A is important for allergic airways hyperreactivity

Background Interleukin (IL)‐25 (IL‐17E) is a potent inducer of the type‐2 immune effector response. Previously we have demonstrated that a neutralizing anti‐IL‐25 antibody, given during the establishment of ovalbumin‐specific lung allergy, abrogates airways hyperreactivity. Objective Blocking IL‐25 results in the suppression of IL‐13, a cytokine known to exacerbate pulmonary inflammation, and an unexpected reciprocal increase in IL‐17A. The role of IL‐17A in asthma is complex with reports of both pro‐inflammatory and anti‐inflammatory functions. Our aim was to determine the influence of IL‐17A in regulating IL‐25‐dependent lung allergy. Method Neutralizing antibodies to IL‐25 and/or IL‐17A were administered during an experimental model of allergic asthma. Bronchoalveolar cell infiltrates and lung cytokine production were determined to assess lung inflammation. Invasive plethysmography was undertaken to measure lung function. Results Neutralization of IL‐25 correlated with a decrease in IL‐13 levels and an increase in IL‐17A production, and an accompanying prevention of airway hyperresponsiveness (AHR). Notably, the blocking of IL‐17A reversed the protective effects of treating with anti‐IL‐25 antibodies, resulting in the re‐expression of several facets of the lung inflammatory response, including IL‐13 and eotaxin production, eosinophilia and AHR. Using mice over‐expressing IL‐13 we demonstrate that treatment of these mice with anti‐IL‐25 fails to suppress IL‐13 levels and in turn IL‐17A levels remain suppressed. Conclusions and Clinical Relevance IL‐13 is known to be an important inducer of lung inflammation, causing goblet cell hyperplasia and promoting airways hyperreactivity. Our data now demonstrate that IL‐13 also plays an important role in the genesis of lung inflammation downstream of IL‐25 by suppressing a protective IL‐17A response. These findings also highlight the important reciprocal interplay of the IL‐17 family members, IL‐25 and IL‐17A, in regulating allergic lung responses and suggest that the balance of IL‐17A, together with IL‐25, will be an important consideration in the treatment of allergic asthma. Cite this as: J. L. Barlow, R. J. Flynn, S. J. Ballantyne and A. N. J. McKenzie, Clinical & Experimental Allergy, 2011 (41) 1447–1455.     

Characterization of innate immune signalling receptors in virus‐induced acute asthma

Background The role of toll‐like receptors (TLRs) and innate immune activation in clinical asthma exacerbations and their relationship to virus infection are unclear. Objective This study aimed to characterize TLR expression and innate immune activity during virus infection in acute asthma. Methods Subjects with acute asthma, stable asthma and healthy controls were recruited and underwent spirometry and sputum induction with isotonic saline. Selected sputum was dispersed with dithiothreitol and total and differential leucocyte counts were performed. Selected sputum was also used for quantitative real‐time PCR for TLR2, TLR3, TLR4, IL‐10 and IP‐10mRNA expression. Sputum supernatant was used for the measurement of innate immune markers, including IL‐8, matrix metalloproteinase‐9 and neutrophil elastase activity. Viruses were detected using real‐time and gel‐based PCR. Results Sputum TLR2 mRNA expression was up‐regulated in both acute and stable asthma compared with healthy controls and decreased 4–6 weeks after acute exacerbation. Sputum TLR2 mRNA expression was elevated in viral, compared with non‐viral, acute asthma. Sputum TLR3 mRNA expression was similar in controls, stable and acute asthma. However, in acute asthma, subjects with virus‐induced acute asthma had significantly higher sputum TLR3 mRNA expression. Induced sputum gene expression for IP‐10 and IL‐10 were increased in viral, compared with non‐viral, acute asthma. In virus‐induced acute asthma, levels of IP‐10 and IL‐10 mRNA expression were correlated with the mRNA expression of TLR2 and TLR3. Conclusions and Clinical Relevance Virus‐induced acute asthma leads to specific induction of TLR2, TLR3, IP‐10 and IL‐10, suggesting that signalling via TLRs may play an important role in mediating airway inflammation, via both innate and adaptive pathways, in virus‐induced exacerbations. These mediators may provide potential treatment targets for virus‐induced asthma. They may also be useful in diagnosing the nature of acute asthma exacerbations and monitoring treatment responses, which would be useful in the clinical management of asthma exacerbations. Cite this as: L. G. Wood, J. L. Simpson, P. A. B. Wark, H. Powell and P. G. Gibson, Clinical & Experimental Allergy, 2011 (41) 640–648.     

Leishmania expressed lipophosphoglycan interacts with Toll‐like receptor (TLR)‐2 to decrease TLR‐9 expression and reduce anti‐leishmanial responses

Two different Toll‐like receptors (TLRs) have been shown to play a role in host responses to Leishmania infection. TLR‐2 is involved in parasite survival in macrophages upon activation by lipophosphoglycan (LPG), a virulence factor expressed by Leishmania. In contrast, activation of TLR‐9 has been shown to promote a host‐protective response. However, whether there is a relationship between the interaction of LPG and TLR‐2, on one hand, with the effect of TLR‐9, on the other hand, remains unknown. In this study, we report that in‐vitro infection of macrophages with a L. major parasite with high expression levels of LPG results in decreased TLR‐9 expression compared to infection with a L. major parasite with lower expression levels of LPG. Addition of anti‐LPG as well as anti‐TLR‐2 antibodies prevents this reduction of TLR‐9 expression. Also, the addition of purified LPG to macrophages results in a decrease of TLR‐9 expression, which is shown to be mediated by transforming growth factor (TGF)‐β and interleukin (IL)‐10. Finally, in‐vitro treatment of macrophages with anti‐LPG and/or anti‐TLR‐2 antibodies before infection reduces the number of amastigotes in macrophages and co‐treatment of mice with anti‐TLR‐2 antibodies and cytosine–phosphate–guanosine (CpG) reduces footpad swelling and parasite load in the draining lymph nodes, accompanied by an interferon (IFN)‐γ‐predominant T cell response. Thus, for the first time, we show how interactions between LPG and TLR‐2 reduce anti‐leishmanial responses via cytokine‐mediated decrease of TLR‐9 expression.     

The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF‐α

The P2×7 receptor (P2×7r) is expressed in innate immune cells (e.g. monocyte/macrophages), playing a key role in IL‐1β release. Since innate immune activation and IL‐1β release seem to be implicated in Behçet's disease (BD), a systemic immune‐inflammatory disorder of unknown origin, we hypothesized that P2×7r is involved in the pathogenesis of the disease. Monocytes were isolated from 18 BD patients and 17 healthy matched controls. In BD monocytes, an increased P2×7r expression and Ca²⁺ permeability induced by the selective P2×7r agonist 2′‐3′‐O‐(4‐benzoylbenzoyl)ATP (BzATP) was observed. Moreover, IL‐1β release from LPS‐primed monocytes stimulated with BzATP was markedly higher in BD patients than in controls. TNF‐α‐incubated monocytes from healthy subjects almost reproduced the findings observed in BD patients, as demonstrated by the increase in P2×7r expression and BzATP‐induced Ca²⁺ intake. Our results provide evidence that in BD monocytes both the expression and function of the P2×7r are increased compared with healthy controls, as the possible result, at least in part, of a positive modulating effect of TNF‐α on the receptor. These data indicate P2×7r as a new potential therapeutic target for the control of BD, further supporting the rationale for the use of anti‐TNF‐α drugs in the treatment of the disease.     

Association of toll‐like receptor 4 polymorphisms with type 2 diabetes mellitus

Toll‐like receptor 4 (TLR4) plays important roles in modulating innate immunity. Type 2 diabetes mellitus (T2DM) is a chronic and complex disease that is characterized by impaired insulin resistance and dysregulated immune response. In the current study, we investigated whether TLR4 polymorphisms were correlated with susceptibility to T2DM in the Chinese population. Four TLR4 polymorphisms (?2431T/C, Asp299Gly, Thr399Il3, and +3725G/C) were genotyped in 936 T2DM patients and 978 healthy controls. Results showed that the prevalence of TLR4 +3725GC and CC genotypes was significantly decreased in T2DM cases than those in controls [odds ratio (OR) = 0.68, 95% confidence interval (CI) = 0.55–0.84, p = 0.0003, and OR=0.46, 95% CI = 0.32–0.67, p = 3.71 × 10^?5, respectively). Also, the frequency of TLR4 +3725C allele was significantly lower in T2DM patients (p = 2.50 × 10^?8). The ?2431T/C did not reveal any significant differences between cases and controls. We did not detect Asp299Gly and Thr399Il3 polymorphisms in our study group. Stratification analysis of the clinical features in the patients demonstrated that frequency of +3725CC genotype was lower in patients older than 50 years old (p = 0.047). In conclusion, these results indicate that TLR4 +3725G/C polymorphism may be a novel protective factor against T2DM in the Chinese population.     

NK cell‐extrinsic IL‐18 signaling is required for efficient NK‐cell activation by vaccinia virus

NK cells are important for the control of vaccinia virus (VV) in vivo. Recent studies have shown that multiple pathways are required for effective activation of NK cells. These include both TLR‐dependent and ‐independent pathways, as well as the NKG2D activating receptor that recognizes host stress‐induced NKG2D ligands. However, it remains largely unknown what controls the upregulation of NKG2D ligands in response to VV infection. In this study using C57BL/6 mice, we first showed that IL‐18 is critical for NK‐cell activation and viral clearance. We then demonstrated that IL‐18 signaling on both NK cells and DCs is required for efficient NK‐cell activation upon VV infection in vitro. We further showed in vivo that efficient NK‐cell activation in response to VV is dependent on DCs and IL‐18 signaling in non‐NK cells, suggesting an essential role for NK cell‐extrinsic IL‐18 signaling in NK‐cell activation. Mechanistically, IL‐18 signaling in DCs promotes expression of Rae‐1, an NKG2D ligand. Collectively, our data reveal a previously unrecognized role for NK cell‐extrinsic IL‐18 signaling in NK‐cell activation through upregulation of NKG2D ligands. These observations may provide insights into the design of effective NK‐cell‐based therapies for viral infections and cancer.     

Physiological aspects of Toll‐like receptor 4 activation in sepsis‐induced acute kidney injury

Sepsis‐induced acute kidney injury (SI‐AKI) is common and associated with high mortality. Survivors are at increased risk of chronic kidney disease. The precise mechanism underlying SI‐AKI is unknown, and no curative treatment exists. Toll‐like receptor 4 (TLR4) activates the innate immune system in response to exogenous microbial products. The result is an inflammatory reaction aimed at clearing a potential infection. However, the consequence may also be organ dysfunction as the immune response can cause collateral damage to host tissue. The purpose of this review is to describe the basis for how ligand binding to TLR4 has the potential to cause renal dysfunction and the mechanisms by which this may take place in gram‐negative sepsis. In addition, we highlight areas for future research that can further our knowledge of the pathogenesis of SI‐AKI in relation to TLR4 activation. TLR4 is expressed in the kidney. Activation of TLR4 causes cytokine and chemokine release as well as renal leucocyte infiltration. It also results in endothelial and tubular dysfunction in addition to altered renal metabolism and circulation. From a physiological standpoint, inhibiting TLR4 in large animal experimental SI‐AKI significantly improves renal function. Thus, current evidence indicates that TLR4 has the ability to mediate SI‐AKI by a number of mechanisms. The strong experimental evidence supporting a role of TLR4 in the pathogenesis of SI‐AKI in combination with the availability of pharmacological tools to target TLR4 warrants future human studies.